已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

医学 卡培他滨 队列 内科学 乳腺癌 肿瘤科 转移性乳腺癌 曲妥珠单抗 临床终点 放射治疗 癌症 队列研究 外科 临床试验 结直肠癌
作者
Min Yan,Quchang Ouyang,Tao Sun,Limin Niu,Jin Yang,Li Li,Yuhua Song,Chunfang Hao,Zhan‐Hong Chen,Armando Orlandi,Naohiro Ishii,Kazuaki Takabe,Gianluca Franceschini,Francesco Ricci,Claire F. Verschraegen,Zhenzhen Liu,Mengwei Zhang,Huimin Lv,Liping Liu,Yang Xiao-hong
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (3): 353-361 被引量:122
标识
DOI:10.1016/s1470-2045(21)00716-6
摘要

Background Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Efficacious treatment options are scarce. We investigated the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases. Methods We did a multicentre, single-arm, two-cohort, phase 2 trial in eight tertiary hospitals in China. Patients aged 18 years or older who had radiotherapy-naive HER2-positive brain metastases (cohort A) or progressive disease after radiotherapy (cohort B), with an Eastern Cooperative Oncology Group performance status of 0–2, received pyrotinib 400 mg orally once daily, and capecitabine 1000 mg/m2 orally twice daily for 14 days, followed by 7 days off every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was confirmed intracranial objective response rate by investigator assessment according to the Response Evaluation Criteria In Solid Tumours (version 1.1). Activity and safety were analysed in patients with at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov, NCT03691051. Findings Between Jan 29, 2019, and July 10, 2020, we enrolled 78 women: 51 (86%) of 59 patients in cohort A and 18 (95%) of 19 patients in cohort B had previous exposure to trastuzumab. Median follow-up duration was 15·7 months (IQR 9·7–19·0). The intracranial objective response rate was 74·6% (95% CI 61·6–85·0; 44 of 59 patients) in cohort A and 42·1% (20·3–66·5; eight of 19 patients) in cohort B. The most common grade 3 or worse treatment-emergent adverse event was diarrhoea (14 [24%] in cohort A and four [21%] in cohort B). Two (3%) patients in cohort A and three (16%) in cohort B had treatment-related serious adverse events. No treatment-related deaths occurred. Interpretation To our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population. This combination deserves further validation in a randomised, controlled trial. Funding National Cancer Centre Climbing Foundation Key Project of China, Jiangsu Hengrui Pharmaceuticals. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
彭于晏的应助被科研通管家采纳,获得10
1秒前
笙笙的应助被科研通管家采纳,获得10
1秒前
斯文败类的应助被科研通管家采纳,获得10
2秒前
2秒前
万能图书馆的应助被上善若水采纳,获得10
2秒前
笙笙的应助被科研通管家采纳,获得10
2秒前
汉堡包的应助被科研通管家采纳,获得10
2秒前
田様的应助被科研通管家采纳,获得10
2秒前
ffff完成签到 ,获得积分10
6秒前
兰高锋发布了新的文献求助30
6秒前
温暖无招完成签到 ,获得积分10
10秒前
17完成签到,获得积分10
10秒前
贪玩千儿完成签到,获得积分10
12秒前
liza发布了新的文献求助10
16秒前
爆米花的应助被YCLING采纳,获得10
16秒前
JamesPei的应助被wjw采纳,获得30
20秒前
nanfeng完成签到 ,获得积分10
23秒前
陶醉成协完成签到,获得积分10
23秒前
隐形曼青的应助被刻苦乐天采纳,获得10
23秒前
黎明深雪完成签到 ,获得积分10
25秒前
鲅鱼饺子完成签到 ,获得积分10
26秒前
热情的水杯完成签到,获得积分10
26秒前
如梦完成签到 ,获得积分10
27秒前
Hello的应助被旺仔仔采纳,获得10
27秒前
30秒前
31秒前
YCLING发布了新的文献求助10
33秒前
34秒前
moriaty发布了新的文献求助20
38秒前
刻苦乐天发布了新的文献求助10
39秒前
斯文紫菜完成签到 ,获得积分10
40秒前
勤奋的含蕾完成签到 ,获得积分10
43秒前
林lin完成签到,获得积分10
45秒前
zz完成签到,获得积分10
46秒前
46秒前
甜甜紫寒完成签到 ,获得积分10
46秒前
英姑的应助被liza采纳,获得10
52秒前
54秒前
58秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082